Format

Send to

Choose Destination
See comment in PubMed Commons below
Ann Rheum Dis. 2015 Mar;74(3):499-505. doi: 10.1136/annrheumdis-2013-203923. Epub 2013 Dec 2.

MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.

Author information

1
Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands.
2
Department of Paediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany.
3
Institute of Immunology, University Hospital Muenster, Muenster, Germany.
4
Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, The Netherlands University of Cambridge, Cambridge, UK GlaxoSmithKline, Stevenage, UK.
5
Department of Paediatric Rheumatology and Immunology, University Children's Hospital Muenster, Muenster, Germany Institute of Immunology, University Hospital Muenster, Muenster, Germany.

Abstract

BACKGROUND:

One-third of rheumatoid arthritis (RA) patients treated with biological therapy show lack of response. The use of predictive biomarkers to identify responders to treatment may provide guidance in optimising treatment strategies and reduce unnecessary side effects and costs.

OBJECTIVE:

To test the ability of myeloid-related proteins (MRP)8/14 protein complexes, an endogenous TLR-4 receptor agonist, to predict and monitor response to biologics in RA patients.

METHODS:

170 RA patients treated with adalimumab (n=86), infliximab (n=60) or rituximab (n=24) were categorised into clinical responders (n=123) and non-responders (n=47). MRP8/14 serum complexes were measured at baseline, and 4 and 16 weeks after initiation of treatment and related to response outcome.

RESULTS:

Before initiation of treatment, responders showed significantly higher MRP8/14 protein complex levels compared with non-responders in each prospective cohort (p=0.010, p=0.001 and p<0.001, respectively). Logistic regression analysis showed that having high MRP8/14 baseline levels increased the odds of being a responder by 3.3 up to 55. In responders to adalimumab or infliximab treatment, MRP8/14 levels decreased after 4 weeks of treatment by 46% and 60% and after 16 weeks by 61% and 68%, respectively. In contrast, MRP8/14 levels were stable in non-responders. In patients treated with rituximab, MRP8/14 levels decreased by 59% after 16 weeks in responders and increased by 89% after 16 weeks in non-responders.

CONCLUSION:

Serum concentrations of MRP8/14 protein complex are a promising biomarker to predict response to biological therapy in active RA patients at baseline and could be used to monitor response to treatment across different mechanisms of action.

KEYWORDS:

Anti-TNF; Disease Activity; Rheumatoid Arthritis

PMID:
24297376
DOI:
10.1136/annrheumdis-2013-203923
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center